Results 91 to 100 of about 1,011,036 (303)

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Acceptance and Commitment Therapy group for treatment-resistant participants: a randomized controlled trial

, 2014
Acceptance and Commitment Therapy (ACT) is a theoretically coherent approach addressing common processes across a range of disorders. The aim of this study was to investigate the effectiveness of a group-based ACT intervention for ‘treatment-resistant ...
Clarke, Sue, James, Kirsty, Remington, Bob, Remington, B., James, K., Kingston, Jessica, Kingston, J., Bolderston, Helen   +7 more
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Heritability of variation in glycaemic response to metformin:a genome-wide complex trait analysis [PDF]

, 2014
Background: Metformin is a first-line oral agent used in the treatment of type 2 diabetes, but glycaemic response to this drug is highly variable.
Ahlqvist, Emma,, Deshmukh, Harshal, Pearson, Ewan R., Deshmukh, H, Colhoun, Helen M, Morris, Andrew D., Morris, Andrew D, Groop, Leif,, Colhoun, HM, McCarthy, Mark I, Zhou, K, Palmer, Colin N A, Yang, J, Palmer, Colin N.A.; id_orcid, Zuydam, NV, Groop, L, Sham, Pak C, McCarthy, Mark, Spencer, Chris C, Donnelly, Lousie, Palmer, Colin N. A., Spencer, Chris C., Zhou, KX, Yang, Jian, Spencer, CC, Lund University., Palmer, CN, Donnelly, Louise, Li, M, McCarthy, MI, Van Zuydam, Natalie, Palmer, CNA, Zhou, Kaixin, Spencer, Chris, Pearson, Ewan R.; id_orcid, McCarthy, ML, Donnelly, L, Van Zuydam, N, Li, Miaoxin, Morris, AD, Groop, Leif, Sham, PC, McCarthy, Mark I., Ahlqvist, E, Groop, Lief, Pearson, Ewan R, Pearson, ER, Colhoun, Helen M., Sham, Pak C., Ahlqvist, Emma   +49 more
core   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Mixture randomized item-response modeling: a smoking behavior validation study [PDF]

, 2013
Misleading response behavior is expected in medical settings where incriminating behavior is negatively related to the recovery from a disease. In the present study, lung patients feel social and professional pressure concerning smoking and experience ...
Avetisyan, M., Fox, J.-P., van der Palen, J.; id_orcid, van der Palen, J.   +3 more
core   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Optimal strategy for improved estimation of population mean of sensitive variable using non-sensitive auxiliary variable

Journal of Big Data
To improve the transformed ratio type estimators, this study uses new population parameters that are derived from extra information using a randomized response technique (RRT).
Abdullah A. Zaagan, Dinesh K. Sharma, Ali M. Mahnashi, Mutum Zico Meetei, Subhash Kumar Yadav, Aakriti Sharma, Pranav Sharma   +6 more
doaj   +1 more source

The effect of a voucher incentive on a survey response rate in the clinical setting: a quasi-randomized controlled trial

BMC Medical Research Methodology, 2018
Background Financial rewards have been shown to be an important motivator to include normal healthy volunteers in trials. Less emphasis has been put on non-healthy volunteers.
Dawid Pieper, Nina Kotte, Peggy Ober
doaj   +1 more source

Innovative improvements in randomized response models

, 2019
The estimation of the relative size of a certain subgroup within a population under study is one of the most important tasks in statistical surveys. When the question on the membership of the subgroup is sensitive, for example, membership in a group in ...
Yennum, Niharika
core